On April 4, 2022 Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, reported preliminary results from an ongoing Phase 1 trial evaluating TTX-030 in combination with chemoimmunotherapy for the first-line treatment of patients with locally advanced or metastatic HER2- gastric or gastroesophageal junction (GEJ) cancer will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 taking place in New Orleans, LA, April 8-13, 2022 (Press release, Trishula Therapeutics, APR 4, 2022, View Source [SID1234611424]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR Oral Presentation Details:
Title: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the 1st line treatment of locally advanced or metastatic gastric/GEJ cancer.
Abstract Number: 8213
Session Title: Combination Immunotherapy Clinical Trials
Session Date and Time: Tuesday, April 12, 2022, 10:15 to 12:15 p.m., Central Time
Location: Hall B-C, Convention Center
Presentation Number: CT015